anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study investigated the nausea-like behavior induced by road transportation in goats, and the effects of an anti-motion sickness (MS) medication on this behavior. In the first experiment, 11 adult Shiba goats were road transported twice with either a saline (control) or a commercial anti-MS medication (Travelmin) injection at the first or second transportation. Almost all goats showed nausea-like behavior, which was defined as pointing their heads downward, closing their eyes, and staying relatively still. These goats did not respond when they were touched during blood collection. The anti-MS medication significantly reduced the total time spent in nausea-like behavior (P < 0.05) and tended to increase the frequency of escape attempts during blood collection (P < 0.1). In a second experiment, the effects of the anti-MS medication were examined in goats held under normal housing. The anti-MS medication increased the time spent feeding (P < 0.01) and reduced the time spent in rumination (P < 0.05) but did not change the frequency of lying down nor plasma cortisol concentrations. Our results indicate that the nausea-like behavior in transported goats might be induced, at least in part, by regulatory mechanisms similar to the MS.
An insulin-loaded ZIF-8 and a response type insulin delivery system, a preparation method and application thereof, belonging to the field of biological medical materials. The ZIF-8 loaded with insulin is prepared by taking ZIF-8 as a carrier and loading insulin through a one-pot method. The encapsulation efficiency is higher by adjusting the preparation process. Also provided is a responsive insulin delivery system comprising insulin-loaded ZIF-8, glucose oxidase, a gel matrix and adjuvants. The gel matrix of the system selects poloxamer with good biocompatibility and degradability. The responsive insulin delivery system is prepared by a cold dissolving method. The use of the responsive insulin delivery system described above for its hypoglycemic effect has also been investigated. The discovery shows that the insulin release amount can be regulated according to the blood sugar level in vivo to avoid the hypoglycemia risk, and the gel matrix can slow down the drug release speed and prolong the drug action time.
The invention relates to medicine for treating meniscus injury, and also relates to sodium hyaluronate and lincomycin as well as the application of the lincomycin in the medicine for treating meniscus injury. The medicine for treating meniscus injury is characterized by comprising the lincomycin, wherein the lincomycin is a common fungistat in the prior art and can perform the action on fighting bacterium and diminishing inflammation. The medicine for treating meniscus injury finds that the lincomycin has the action on repairing a meniscus cell, and therefore the medicine for treating meniscus injury can serve as the medicine for repairing the meniscus injury and has a good curative effct. The medicine for treating meniscus injury is combined with the sodium hyaluronate and hexadecadrol, and has a better curative effect. The sodium hyaluronate serves as a nutrient substance to simultaneously perform the action on providing articular cavity pressure, supporting joint movement and lubricating joints, and is also convenient for dispersing other medicines, such as lincomycin. The hexadecadrol has the action on enhancing the medicine effect of the lincomycin. Several medicines are cooperated to perform a better treating effect.
EXCL-100, 1200 mg (600 mg oral tablet x 2), twice daily with meals (BID, every 12 hours) for 3 days, total daily dose of 2400 mg, given under fed conditions. Subjects will receive a single dose on Day 4 after breakfast.
The invention discloses a lipidosome with entrapment nucleic acid drugs, an anaerobic response capability and a radiotherapy sensitivity enhancing function. The lipidosome comprises a lipidosome body and nucleic acid drugs. The lipidosome is prepared from, by mass, 20-80% of lipid molecules with the radiotherapy sensitivity enhancing function, 5-50% of cholesterol, 3-50% of polyethylene glycol phospholipid and 1-30% of DOPC lipid molecules. The N/P ratio of the lipidosome to nucleic acid in the nucleic acid drugs is 1:(1-20). The obtained lipidosome overcomes the defects that the positive ion lipidosome toxicity is high, the blood stability is poor and the transfection efficiency is low, the effect of the nucleic acid drugs is effectively improved, meanwhile the lipidosome has the high endosome escape capability under the oxygen-deficient environment, so that the obvious advantage of transfection of gene-based drugs is achieved. The lipidosome is applicable to entrapment of various nucleic acid drugs, and the applicable dosage form range is wide.
Pancreatic cancer, with its associated poor prognosis, is one of the most insidious and lethal cancers globally. Indeed, pancreatic cancer has been listed as the fourth leading cause of cancer-related deaths in developed countries, and it may replace colorectal cancer as the second-leading cause of cancer-related deaths by 2030. Pancreaticoduodenectomy is the standard treatment for periampullary carcinoma, especially pancreatic head tumors. However, the incidence of postoperative complications, especially postoperative pancreatic fistula, remains as high as 25%-50%, which limits the dissemination of pancreaticoduodenectomy.

An external pancreatic duct stent is one of the methods used to prevent pancreatic fistula. A large number of studies, including prospective randomized trials as well as meta-analyses, have shown that external pancreatic duct stents significantly decrease the rate of pancreatic fistula and shorten the length of hospital stay. Paradoxically, several studies have shown that external pancreatic duct stents have no effect and may even increase the incidence of postoperative pancreatic fistula. In a meta-analysis, Dong et al. observed that the use of an external pancreatic duct stent was associated with a significantly lower incidence of pancreatic fistula in patients at high risk for pancreatic fistula compared with an internal stent, but there was no definitive conclusion because of the low quality of the evidence.

In 2019, Mungroop et al. proposed the Updated Alternative Fistula Risk Score (ua-FRS) according to the International Study Group of Pancreatic Surgery (ISGPS), which quantitatively validated the risk of pancreatic fistula and assessed the benefits of pancreatic duct stents in patients at different levels of risk. Moreover, ISGPS redefined the classification criteria for pancreatic fistula (Grade A) as a biochemical leak, which had no significant clinical impact on the clinical prognosis. In addition, the position statement by ISGPS indicated that, due to the lack of high-quality evidence, the pancreatic duct stent was not routinely recommended during pancreaticoenteric anastomosis, but external stenting can be considered in high-risk glands. Therefore, it is necessary to systematically re-investigate the safety and effectiveness of external pancreatic duct stents for the prevention and treatment of clinically relevant postoperative pancreatic fistula (CR-POPF) in both high-risk and low-risk patients. This retrospective study was conducted to evaluate the differences between external and internal pancreatic stents using the ua-FRS scoring system, based on the hypothesis that the use of an external stent in high-risk patients could decrease the rates of CR-POPF compared with an internal stent after pancreaticoduodenectomy.
A recirculating high pressure lipid extractor includes a kettle with a sealed interior configured for pressurizing and heating a fluid mixture. A flow funnel is positioned in a lower portion. A removable material basket is positioned on top of the flow funnel in an upper section. The removable material basket is configured to hold a material inside the removable material basket. A drain and inlet port is at a bottom of the kettle in communication with the sealed interior of the kettle. A recirculation port is approximate a top of the kettle in communication with the sealed interior of the kettle. Wherein, when the fluid mixture is inserted into the kettle, the recirculating high pressure lipid extractor is configured to pressurize and heat the fluid mixture and recirculate the pressurized and heated fluid mixture from the recirculation port into the drain and inlet port.
The goal of this protocol is to establish a cohort of biologic samples collected prospectively from patients treated in BMT CTN centers that will be a shared bio specimen resource for conducting future allogeneic HCT correlative studies. This resource is designed to allow genomic, proteomic and transcriptional data to be integrated with high quality clinical phenotype and outcomes data to identify risk factors for development and severity of acute GVHD, chronic GVHD, organ toxicity, relapse, mortality, infection and other clinically significant complications occurring after allogeneic HCT.

To achieve this goal, patients and donors will be recruited and consent obtained at the time that they enroll on BMT CTN protocols where enrollment occurs at or before transplantation or prior to start of conditioning for patients enrolled on non-BMT CTN studies or treated as standard of care. Samples will be collected: (1) from patients and donors pre-transplant; and, (2) from patients post-transplant on a calendar schedule through the first 3 months post-HCT. For patients co-enrolled on BMT CTN studies, clinical data will be collected in the context of the primary transplant protocols. For patients not enrolled on BMT CTN protocols, clinical data on early post-transplant events will be collected using the same data collection forms and systems that are used on BMT CTN trials. Additional clinical data for both BMT CTN and non-BMT CTN patients will be available from data submitted to the Center for International Blood and Marrow Transplant Research (CIBMTR) using the CIBMTR Comprehensive Report Forms. This protocol also leverages ongoing pre-transplant donor-recipient sample collection performed by the CIBMTR and National Marrow Donor Program (NMDP). Success in establishing this shared resource will inspire future investigator initiated research proposals and will allow investigators to take advantage of National Institutes of Health (NIH) funding initiatives.
The present invention relates to a medicine composition for curing functional indigestion and a preparation method thereof. Malt, mssa medicata fermentata, radish seed, white atractylodes rhizome, perilla leaf, prepared liauorice root, officinal magnolia bark, dandelion and corydalis tuber are prepared into traditional Chinese medicine prepared in ready-to-use forms according to certain proportions by the standard. By an animal toxicity test result, the present invention indicates that mouse stomachs are poured by medicine compositions of 166.7 times than that of adults, and no acute toxicity reactions occur. Pharmacodynamics research indicates that a medicine composition is capable of promoting gastric emptying and duodenum movement, increases the amount of gastric secretion and promotes peptic secretion. The clinical manifestation and the sign of a curing group and a contrast group explain that functional indigestion predominatingly takes epigastric ache, epigastric distention and epigastric tenderness. The curing group obtains obvious curing effects, and a total effective rate is 96.15%. Compared with the contrast group, the curing group has obvious difference and no toxic side effects. The present invention is clinically used for over four years. By clinical curative effects and pharmacodynamics research, the medicine composition indicates has the efficacy of removing food retention, relieving dyspepsia, strengthening the spleen, eliminating dampness, regulating qi flow for relieving pain and is effectively special medicine for curing functional indigestion.
In sham condition, the stimulation only last for 30 seconds with the electrodes left in place for a further 20 minutes. This procedure mimics the transient skin sensation of tingling induced by active HD-tACS and HD-tDCS without producing any sustainable effects.
EHOA was diagnosed according to the American College of Rheumatology (ACR) criteria and to the presence of the classical central erosion in at least two IP joints. Further inclusion criteria were the availability of plain radiography of both hands performed in the previous 6 months. Plain radiographs of both hands were collected and scored by two readers according to Kallman's classification in a blind observation.
This advice generation device (10) comprises: an information acquisition unit (110); a rule acquisition unit (120); a blood sugar level estimation unit (130); and an advice generation unit (140). The information acquisition unit (110) acquires a first blood sugar level, which is a blood sugar level of a subject at a first timing, meal information, which is information about a meal ingested by the subject after the first timing, and a reference range of the blood sugar level of the subject. The rule acquisition unit (120) acquires a blood sugar level estimation rule. The blood sugar level estimation rule is set for each subject, and a second blood sugar level, which is a blood sugar level at a second timing after the subject has had a meal, is estimated using the first blood sugar level and the meal information. The blood sugar level estimation unit (130) estimates a second blood sugar level by using the first blood sugar level, the meal information, and the blood sugar level estimation rule. The advice generation unit (140) generates advice information. The advice information is advice about a meal, for example.
Engaging Men through Accountable Practice: 30 communities are matched into 15 pairs on a set of socio-demographic characteristic and within each pair, 15 treatment sites are randomly selected. Within each treatment community, all adult men (20+ years old) are eligible to participate in the EMAP intervention. A random draw of 50 participants determines who will participate in EMAP in case more than 50 eligible men express interest.
The invention relates to an anti-thrombosis polypeptide valid target in Vespula spp. insects. The valid target is prepared by the following steps: dialyzing Vespula spp. insect crude bee venom with a 25kDa dialysis membrane, and carrying out freeze-drying or vacuum concentration and drying on the dialysis solution. A series of pharmacodynamic experiments by people prove that the biotoxin polypeptide valid target and a transdermal absorption preparation thereof have obvious effects on preventing and treating cerebral thrombosis, restoring mobility of animals with cerebral palsy, preventing and treating platelet accumulation and relieving ischemic brain injury, and have better pharmacodynamic performance than Plavix, Xingnaojing injection and other first-tier medicines. The valid target is expected to be used for preparing innovative biochemical medicines for treating cardiovascular and cerebrovascular diseases and for preventing and treating ischemic cardiovascular and cerebrovascular diseases, such as myocardial infarction, cardiovascular thrombosis, cerebral thrombosis, cerebral infarction, acute/chronic cerebral apoplexy, and sequelae caused by cerebral infarction injury, including hemiplegia, hemidysesthesia, hemianopsia, facioplegia, paralysis lingualis, aphasia, pamplegia and the like.
OBJECTIVE: To investigate the effect and potential mechanisms of α-cyperone (CYP) on Crohn's disease (CD) -like colitis induced by 2, 4, 6-trinitrobenzene sulfonic acid (TNBS) in mice.
METHODS: The mice were randomly and evenly divided into wild type (WT), TNBS, CYP and 5-aminosalicylic acid (5-ASA) groups, with 10 mice in each group. The symptoms of enteritis, the function and structure of the intestinal barrier, and the expression levels of inflammatory factors, including interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and gamma-interferon (IFN-γ), in the colon were assessed. The lipopolysaccharide (LPS)-induced inflammation model of Caco2 cells was constructed and the cells were divided into Control, LPS and LPS+CYP groups. The expression levels of tight junction protein and inflammatory factors in each group were assessed. Gene Ontology (GO) functional enrichment analysis was conducted to predict the possible pathways of action and potential molecular mechanisms of CYP, and to verify them in vivo and in vitro.
RESULTS: In the in vivo study, compared with those of the TNBS group, the body mass and colon length of mice in the CYP group and the 5-ASA group were significantly increased, while the disease activity scores and histological inflammation scores were significantly decreased (P<0.05). The level of lucifcein-glucan isothiocyanate and the bacterial translocation rate (in the liver, the spleen, and mesenteric lymph nodes) were significantly decreased, while the transepithelial electric resistance (TEER) value and the expression levels of zonula occluden protein-1 (ZO-1), and claudin-1 were significantly increased (P<0.05). The expression of inflammatory factors was significantly decreased (P<0.05). In the in vitro study, compared with those of the LPS group, the TEER value and the expression of ZO-1 and claudin-1 in the Caco2 cells in the LPS+CYP group were significantly increased (P<0.05). The expression of inflammatory factors was significantly decreased (P<0.05). Enrichment analysis showed that CYP was correlated with inflammatory response (P<0.001). Western blot results showed that CYP could significantly reduce the expression of key proteins in toll-like receptor 4 (TLR4)/nuclear factor-κB (NF-κB) signaling pathway in vivo and in vitro (P<0.05).
CONCLUSION: CYP may protect the intestinal barrier by antagonizing the inflammatory response of the intestinal mucosa through regulating the expression of the TLR4/NF-κB signaling pathway, thereby alleviating TNBS-induced CD-like colitis in mice.
For year one, this arm will receive no intervention. Usual agriculture production and income will be assessed monthly for one year. Additionally, every season (twice yearly), household food security and usual dietary intake of woman of reproductive age (WRA) and their child aged 6-59 mo will also be collected. After one year of implementation, this group will be offered the Enhanced Homestead Food Production package fully subsidized, as well as training on nutrition, WASH, gender and business/marketing.
Patients diagnosed with bronchiectasis by HRCT by a chest diseases specialist and referred to pulmonary rehabilitation by determining the severity of bronchiectasis with the Modified Reiff Score and Bronchiectasis Severity Index Score will be included in the study.

The cases meeting the inclusion criteria will be randomized and divided into two groups, the groups will be named as Telerehabilitation Exercise Group (TRGr) and Control Group (KGr). TRGr will be given online exercises, synchronized 3 days a week, accompanied by a physiotherapist, via videoconference on the group smartphone. As for the KGr group, a pulmonary rehabilitation information brochure will be given to after the initial evaluation. They will be asked to do the exercises on the brochure. The exercise period will be 8 weeks for both groups. Standard medical treatments for both groups will continue.
Within human-influenced landscapes, pesticides cooccur with a variety of antibiotic stressors. However, the relationship between pesticides removal process and antibiotic resistance gene variation are not well understood. This study explored pesticide (topramezone, TPZ) and antibiotic (polymyxin E, PME) co-contamination using liquid chromatography-tandem mass spectrometry (LC-MS/MS), bacterial-16 S rRNA sequencing and high-throughput quantitative polymerase chain reaction (HT-qPCR) in a soil-earthworm-maize system. After incubating soil for 28 days with TPZ and PME (10 mg kg-1 dry weight), earthworm weight-gain, mortality rates, and maize plant weight-gain only differed slightly, but height-gain significantly decreased. PME significantly increased TPZ-removal in the soil. Accumulation of TPZ in earthworm's tissues may pose potential risks in the food chain. Combined pollution altered the microbial community structure and increased the abundance of functional microorganisms involved in aromatic compound degradation. Furthermore, maize rhizosphere can raise resistance genes, however earthworms can reduce resistance genes. Co-contamination increased absolute abundance of mobile genetic elements (MGEs) in bulk-soil samples, antibiotic resistance genes (ARGs) in skin samples and number of ARGs in bulk-soil samples, while decreased absolute abundance of transposase gene in bulk-soil samples and number of ARGs in rhizosphere-soil samples. Potential hosts harbouring ARGs may be associated with the antagonistic effect during resistance and detoxification of TPZ and PMB co-occurrence. These findings provide insights into the mechanism underlining pesticide removal regarding occurrence of ARGs in maize agroecosystem.
Work participation is essential for quality of life, providing purpose, social interaction, financial security, and shaping social status and personal identity. Work participation is increasingly compromised in people with neurodegenerative movement disorders (NdMD). This negatively impacts their quality of life. People with NdMD lack (structural) work-related support. Early work-related support, focused on sustainable work-retention, has the potential to enhance work participation in people with NdMD. Therefore, the EQuAL-study (Enhancement of Quality of work And Life) investigates the effectiveness of the Participatory Workplace Intervention (PWI), a personalized intervention to enhance quality of work, quality of life and work-life balance. The aim of the study is to investigate study effects of the PWI on need for recovery after work (primary endpoint), perceived self-efficacy at work, work-related well-being, quality of life and absenteeism (secondary outcomes). Additionally, the costs of (not) receiving the PWI will be exploratively evaluated, so as the process of implementation and the intervention's mechanisms of impact. To address these aims, the investigators perform an 18 month single-blind remote randomized controlled trial (RCT). In addition, a process evaluation alongside the RCT will be performed. 124 Dutch working persons with four types of NdMD's will be included: Parkinson's Disease (PD), Atypical Parkinsonism (AP), ataxia and hereditary spastic paraparesis (HSP). Participants will be recruited from approximately twelve regions across the Netherlands. Participants will be randomised to either the PWI or an usual care control group in a 1:1 ratio. The PWI is a process intervention in which a trained process facilitator guides an employee and their manager in identifying work-related obstacles and finding solutions to overcome or manage these obstacles. Its primary goal is to achieve consensus between employee and manager with respect to the most obstructive obstacles for functioning at work and feasible solutions. There are no restrictions on usual care. The study will evaluate between-group differences from baseline to 18-month follow-up in need for recovery after work (primary endpoint) and self-efficacy at work and indicators of quality of life, work-related well-being, and absenteeism (secondary aim). For the third aim, the investigators will measure the costs associated with healthcare use, productivity loss, work-related adjustments, and the intervention. For the fourth aim, the investigators will evaluate the process in terms of implementation of the PWI, the mechanisms of impact and the implementation context. The investigators envision the PWI to support sustainable work retention while preserving work-life balance and quality of life for individuals with NdMD. Additionally, the trial will provide insights into its potential national implementation and application to other neurodegenerative diseases.